Melphalan, a chemotherapy medication is used to treat patients suffering from multiple myeloma, ovarian cancer, melanoma, and amyloidosis. Multiple myeloma, for instance is the second most common blood cancer in United States. The overall 5 years survival rate for a person with multiple myeloma is around 74% and if it is spread to distant part of the body then the survival rate decreases to 51%. Survival rate has increased steadily in the recent years due to advancement in medication and therapies. Melphalan is the most common drug used in the treatment of multiple myeloma, it is given as an intravenous infusion at a high dose rate for patients suffering from multiple myeloma. Additionally, researches are evaluating the use of melphalan for COVID-19 treatment, as the disease is usually accompanied by pneumonia. The melphalan market is gaining more traction in the current COVID-19 pandemic, as companies are increasingly trying to come up with solutions to treat pneumonia caused by coronavirus. Furthermore, there is an increasing focus on treating patients with multiple myeloma and ovarian cancer during the COVID-19 pandemic, since lack of treatment can lead to fatal outcomes for the patients if they’re affected by COVID-19. Thus, there is a rising need for melphalan drugs in the market.
Request for Sample Copy of This Report@ https://www.absolutemarketsinsights.com/request_sample.php?id=721
The growing prevalence of retinoblastoma among patients has led healthcare facilities and medical personnel to look towards alternative treatment methods. The incidences of the tumor have been observed majorly among children which leads in uncontrollable growth of the retinoblasts. Melphalan has been adopted by healthcare facilities in the administration for retinoblastoma. In such cases, it is seen that Melphalan is administered to patients through the arteries using a trans-arterial catheter. The treatment leads to a decreasing risk factor of the tumor in patients. Thus, the effectiveness of this drug for treating cancer patients in the United States, is creating rising opportunities of growth for the melphalan market. Additionally, increasing focus of market participants on merger and acquisitions, rising investment by companies to expand their reach and product portfolio is further aiding for the overall market growth.
The detailed research study provides qualitative and quantitative analysis of melphalan market. The market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across all the major regions. The supply side analysis covers the major market players, their regional presence and strategies. The geographical analysis done emphasizes on each of the major regions across the United States.
Enquiry Before Buying @ https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=721
Key Findings of the Report:
- In terms of revenue, United States melphalan market was valued at US$ 144.41 Mn in 2020 growing at a CAGR of 4.56% over the forecast period (2021 – 2029)
- Based on dosage, tablet, film coated category is expected to grow at the fastest rate over the forecast period.
- Based on route, intra-arterial, intravenous 50 mg/10 ml accounted for the major market share in 2020 in the United States melphalan market. However, oral (2 mg/1, 2MG, 5MG) route of administration is expected to grow at the fastest growth rate over the forecast period, owing to easier medicine intake through the oral mode.
- Used in some conditioning regimens prior to bone marrow transplant segment under application category, is expected to grow at the fastest growth rate of 7.67% over the forecast period.
- Some of the market participants operating in the United States melphalan market are ApoPharma Inc., Acrotech Biopharma, LLC., CELGENE CORPORATION, Fresenius Kabi USA, LLC, Ingenus Pharmaceuticals, LLC, and Mylan Inc. amongst others.
Request for Customization@ https://www.absolutemarketsinsights.com/request_for_customization.php?id=721
United States Melphalan Market:
- By Dosage
- Kit
- Tablet, Film Coated
- Injection Powder, lyophilized, for Solution
- By Route
- Oral (2 mg/1, 2MG, 5MG)
- Intra-arterial, Intravenous 50 mg/10 ml
- By Indication
- Multiple Myeloma
- Ovarian Cancer
- Neuroblastoma
- Rhabdomyosarcoma
- Breast Cancer
- Used in some Conditioning Regimens Prior to Bone Marrow Transplant
- Non-resectable Epithelial Carcinoma of the Ovary
- Recurrent or Unresectable in-transit Metastatic Melanoma
- Treatment of Amyloidosis with Prednisone
- Adjunct to Surgery in the Treatment of Breast Cancer
- Others (Severe Hodgkin Lymphoma, etc.)
- By Region
- Northeast
- Midwest
- West
- South
Get Full Information of this premium report@ https://www.absolutemarketsinsights.com/reports/Melphalan-Market-2020---2028-721
About Us:
Absolute Markets Insights strives to be your main man in your business resolve by giving you insight into your products, market, marketing, competitors, and customers. Visit …
Contact Us:
Email id: [email protected]
Contact Name: Shreyas Tanna
Phone: +91-740-024-2424